Skip to content

Targeting Unmet Needs in Oncology

Home
Technology

SPIRITA Small Logo Transparent 22kb

Post navigation

Previous PostPrevious SPIRITA Small Logo Transparent 22kb

News

August 8, 2020:
BBB Penetrable MEK Inhibitor E6201 Obtained Clinical Trial License in China

December 19, 2018:
Spirita Oncology Initiated Global Clinical Development of E6201 in Collaboration With JS InnoPharm (Shanghai) Under Strategic Partnership Alliance and Sub-license Agreement

May 1, 2018:
Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases

Contact Us

Name *

First

Last

Email *

Subject

Comment or Message *

Phone

Proudly powered by WordPress